Medical editing of this article was provided by Scientific Publications, Research Medical Library, The University of Texas MD Anderson Cancer Center.
Darvin P, Toor SM, Sasidharan Nair V, et al. . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 2018;50:1–11.
Bayle A, Khettab M, Lucibello F, et al. . Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1. Ann Oncol 2020;31:959–961.
Marin-Acevedo JA, Soyano AE, Dholaria B, et al. . Cancer immunotherapy beyond immune checkpoint inhibitors. J Hematol Oncol 2018;11:8.
Singh BP, Marshall JL, He AR. Workup and management of immune-mediated colitis in patients treated with immune checkpoint inhibitors. Oncologist 2020;25:197–202.
Abu-Sbeih H, Ali FS, Naqash AR, et al. . Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol 2019;37:2738–2745.
Abu-Sbeih H, Ali FS, Wang Y. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Curr Opin Gastroenterol 2020;36:25–32.
Abu-Sbeih H, Ali FS, Wang X, et al. . Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2019;7:93.
Som A, Mandaliya R, Alsaadi D, et al. . Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases 2019;7:405–418.
Wang Y, Abu-Sbeih H, Mao E, et al. . Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis 2018;24:1695–1705.
Wang Y, Abu-Sbeih H, Mao E, et al. . Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. J Immunother Cancer 2018;6:37.
Abu-Sbeih H, Ali FS, Qiao W, et al. . Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother 2019;68:553–561.
Wang Y, Wiesnoski DH, Helmink BA, et al. . Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med 2018;24:1804–1808.
Abu-Sbeih H, Tang T, Ali FS, et al. . The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes. J Immunother Precis Oncol 2018;1:7–18.
Fujii Y, Nishikawa Y, Nomura M, et al. . Readministration of nivolumab after persistent immune-related colitis in a patient with recurrent melanoma. Intern Med 2018;57:1173–1176.
Johnson DH, Zobniw CM, Trinh VA, et al. . Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer 2018;6:103.
Abu-Sbeih H, Ali FS, Alsaadi D, et al. . Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer 2018;6:142.
van den Heuvel TR, Wintjens DS, Jeuring SF, et al. . Inflammatory bowel disease, cancer and medication: cancer risk in the Dutch population-based IBDSL cohort. Int J Cancer 2016;139:1270–1280.
Axelrad JE, Lichtiger S, Yajnik V. Inflammatory bowel disease and cancer: the role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol 2016;22:4794–4801.
Taleban S, Elquza E, Gower-Rousseau C, et al. . Cancer and inflammatory bowel disease in the elderly. Dig Liver Dis 2016;48:1105–1111.
Scott SC, Pennell NA. Early use of systemic corticosteroids in patients with advanced NSCLC treated with nivolumab. J Thorac Oncol 2018;13:1771–1775.
Esfahani K, Miller WH Jr. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med 2017;376:1989–1991.
Verheijden RJ, May AM, Blank CU, et al. . Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch Melanoma Treatment Registry. Clin Cancer Res 2020;26:2268–2274.
Horvat TZ, Adel NG, Dang TO, et al. . Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015;33:3193–3198.
- Search Google Scholar
- Export Citation
. , Horvat TZ , Adel NG , Dang TO Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering Cancer Center. J Clin Oncol 2015; 33: 3193– 3198.
The University of Texas MD Anderson Cancer Center. Evaluation and management of suspected immune-mediated colitis/diarrhea. Accessed September 10, 2020. Available at: https://www.mdanderson.org/content/dam/mdanderson/documents/for-physicians/algorithms/clinical-management/clin-management-immune-mediated-colitis-web-algorithm.pdf
Abu-Sbeih H, Faleck DM, Ricciuti B, et al. . Immune checkpoint inhibitor therapy in patients with preexisting inflammatory bowel disease. J Clin Oncol 2020;38:576–583.
Abu-Sbeih H, Ali FS, Luo W, et al. . Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. J Immunother Cancer 2018;6:95.
Choi K, Abu-Sbeih H, Samdani R, et al. . Can immune checkpoint inhibitors induce microscopic colitis or a brand new entity? Inflamm Bowel Dis 2019;25:385–393.
Freedberg DE, Toussaint NC, Chen SP, et al. . Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology 2015;149:883–885.e9.
Ducarmon QR, Zwittink RD, Hornung BVH, et al. . Gut microbiota and colonization resistance against bacterial enteric infection. Microbiology and molecular biology reviews. Microbiol Mol Biol Rev 2019;83:e00007–00009.
Bonderup OK, Nielsen GL, Dall M, et al. . Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide Danish case-control study. Aliment Pharmacol Ther 2018;48:618–625.
Verhaegh BP, de Vries F, Masclee AA, et al. . High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther 2016;43:1004–1013.
Rogers MAM, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect 2016;22:178.e1–178.e9.
Becattini S, Taur Y, Pamer EG. Antibiotic-induced changes in the intestinal microbiota and disease. Trends Mol Med 2016;22:458–478.
Abu-Sbeih H, Herrera LN, Tang T, et al. . Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. J Immunother Cancer 2019;7:242.
Chaput N, Lepage P, Coutzac C, et al. . Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol 2017;28:1368–1379.
Matson V, Fessler J, Bao R, et al. . The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients. Science 2018;359:104–108.
Routy B, Le Chatelier E, Derosa L, et al. . Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science 2018;359:91–97.